{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:02:33Z","timestamp":1793131353524,"version":"4.5.0"},"reference-count":64,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Topical azelaic acid (AA) is indicated for acne and rosacea, but there is some evidence for its use for other dermatological conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the effectiveness and safety of topical AA for acne vulgaris, rosacea, hyperpigmentation\/melasma, and skin aging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RCTs of at least 6\u2009weeks' treatment duration were eligible for inclusion. Databases including MEDLINE, Embase, CINAHL, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> were searched up to December 2022. Two reviewers were involved in all stages of the systematic review process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010three RCTs met the inclusion criteria. Meta\u2010analyses within 20 rosacea studies demonstrated that erythema severity, inflammatory lesion counts, overall improvement, and treatment success (achieving skin clarity) were significantly improved with AA compared with vehicle after 12\u2009weeks. AA was more effective than metronidazole 0.75% for improved erythema severity, overall improvement, and inflammatory lesion counts. Sixteen acne studies suggest that AA is more effective than vehicle for improving global assessments and reducing acne severity. AA 20% also significantly reduced more lesions than erythromycin gel. Within seven melasma studies, AA 20% was significantly better than vehicle for both severity and global improvement. AA 20% demonstrated significantly better results compared with hydroquinone 2% for global improvement. Very few significant differences between AA and comparators were observed for commonly reported adverse events. No eligible RCTs were found that evaluated skin aging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>AA is more effective than vehicle for rosacea, acne and melasma. Comparisons between AA and other treatments were often equivalent. Where there is equivalence, AA may be a good option for some clinical situations. RCT evidence is needed to evaluate the effectiveness of AA on skin aging.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.15923","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T04:51:18Z","timestamp":1691470278000},"page":"2650-2662","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-7672","authenticated-orcid":false,"given":"Sarah","family":"King","sequence":"first","affiliation":[{"name":"Dermatica Institute of Clinical Excellence  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Campbell","sequence":"additional","affiliation":[{"name":"Dermatica Institute of Clinical Excellence  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3395-2385","authenticated-orcid":false,"given":"Rebecca","family":"Rowe","sequence":"additional","affiliation":[{"name":"Dermatica Institute of Clinical Excellence  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Louise","family":"Daly","sequence":"additional","affiliation":[{"name":"Dermatica Institute of Clinical Excellence  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Moncrieff","sequence":"additional","affiliation":[{"name":"Dermatica Institute of Clinical Excellence  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5860-3785","authenticated-orcid":false,"given":"Catriona","family":"Maybury","sequence":"additional","affiliation":[{"name":"Dermatica Institute of Clinical Excellence  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2494.2004.00233_2.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00039-1"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50746-4"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00372056"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2010.01107.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065851"},{"key":"e_1_2_9_8_1","volume-title":"Acne vulgaris: management","author":"National Institute for Health and Care Excellence (NICE)","year":"2021"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04374.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14355"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20485"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14349"},{"issue":"6","key":"e_1_2_9_14_1","first-page":"17","article-title":"Update on the management of rosacea from the American Acne & Rosacea Society (AARS)","volume":"12","author":"Del Rosso JQ","year":"2019","journal-title":"J Clin Aesthetic Dermatol"},{"key":"e_1_2_9_15_1","unstructured":"Primary Care Dermatology Society.Melasma (syn. chloasma).2022; Available from:https:\/\/www.pcds.org.uk\/clinical\u2010guidance\/melasma\u2010syn\u2010chloasma1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000164"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_9_18_1","volume-title":"Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2077.104915"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80076-3"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02940.x"},{"issue":"59","key":"e_1_2_9_24_1","first-page":"11","article-title":"Efficacy and safety of azelaic acid 20% plus hydroquinone 5% in the management of melasma","volume":"15","author":"Tehrani S","year":"2012","journal-title":"Iran J Dermatol"},{"key":"e_1_2_9_25_1","first-page":"58","article-title":"Double\u2010blind comparison of azelaic acid and hydroquinone in the treatment of melasma","volume":"143","author":"Verallo\u2010Rowell VM","year":"1989","journal-title":"Acta Derm Venereol Suppl"},{"issue":"4","key":"e_1_2_9_26_1","first-page":"3","article-title":"Efficacy and safety of once\u2010daily metronidazole 1% gel compared with twice\u2010daily azelaic acid 15% gel in the treatment of rosacea","volume":"77","author":"Wolf JE","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639109086775"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1991.tb04362.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155599750009906"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903440064"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.248"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639309082150"},{"issue":"6","key":"e_1_2_9_34_1","first-page":"541","article-title":"Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea","volume":"7","author":"Thiboutot DM","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_35_1","unstructured":"Finacea 15% and brimonidine 0.33% gel in the treatment of rosacea \u2013 a pilot study (NCT02147691) \u2013 ClinicalTrials.gov.2015."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70085-X"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"e_1_2_9_38_1","unstructured":"Exploration of safety and efficacy of AzA 15% foam twice a day in rosacea (NCT00617903) \u2013 ClinicalTrials.gov.2013."},{"issue":"6","key":"e_1_2_9_39_1","first-page":"306","article-title":"Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double\u2010blind, vehicle\u2010controlled study","volume":"92","author":"Draelos ZD","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_9_40_1","unstructured":"A study to evaluate the safety and clinical study of azelaic acid gel 15% in patients with moderate facial rosacea (NCT02120924) \u2013 ClinicalTrials.gov.2014."},{"key":"e_1_2_9_41_1","unstructured":"A study to evaluate safety and equivalence of generic azelaic acid foam and Finacea\u00ae foam in participants with rosacea (NCT03287791) \u2013 ClinicalTrials.gov.2019."},{"issue":"6","key":"e_1_2_9_42_1","first-page":"607","article-title":"Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild\u2010to\u2010moderate papulopustular rosacea","volume":"9","author":"del Rosso J","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_43_1","unstructured":"Combination gel and vascular ND in mild to moderate rosacea (NCT01631656) \u2013 ClinicalTrials.gov.2017."},{"issue":"7","key":"e_1_2_9_44_1","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_45_1","first-page":"31","article-title":"Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne","volume":"143","author":"Cunliffe WJ","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.31892"},{"key":"e_1_2_9_47_1","first-page":"35","article-title":"Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin","volume":"143","author":"Katsambas A","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2011.581257"},{"key":"e_1_2_9_49_1","unstructured":"Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris (NCT02058628) \u2013 ClinicalTrials.gov.2017."},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12823"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01914.x"},{"issue":"1","key":"e_1_2_9_52_1","first-page":"13","article-title":"Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris","volume":"7","author":"Thiboutot D","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_53_1","first-page":"45","article-title":"Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline","volume":"143","author":"Hjorth N","year":"1989","journal-title":"Acta Derm Venereol Suppl"},{"issue":"5","key":"e_1_2_9_54_1","first-page":"483","article-title":"Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase\u2010negative staphylococci","volume":"30","author":"Ozkan M","year":"2000","journal-title":"Turkish J Med Sci"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb02856.x"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2011.00580.x"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2019.06.502"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15359"},{"key":"e_1_2_9_59_1","unstructured":"Phase 3 papulopustular rosacea study (NCT01493687) \u2013 ClinicalTrials.gov.2015."},{"key":"e_1_2_9_60_1","unstructured":"Phase 3 papulopustular rosacea study (NCT01494467) \u2013 ClinicalTrials.gov.2015."},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13541"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1047"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17590"},{"issue":"5","key":"e_1_2_9_64_1","first-page":"257","article-title":"Topical azelaic acid, salicylic acid, nicotinamide, Sulphur, zinc and fruit acid (alpha\u2010hydroxy acid) for acne","volume":"2020","author":"Liu H","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.044"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:28:26Z","timestamp":1695108506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/jocd.15923"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15923","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"2023-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}